What is pharmacovigilance?

Why post-approval monitoring is needed

Clinical trials, however rigorous, study a limited number of people for a limited time, so rare or long-term adverse effects may not appear before a medicine is approved. Pharmacovigilance fills this gap by watching the medicine in real-world use across far larger and more varied populations. It is the safety counterpart to the approval process: where approval establishes an acceptable benefit–risk balance on the evidence available, pharmacovigilance continually re-examines that balance as new information accumulates. This is why regulators such as the FDA, the EMA and the MHRA each run safety-monitoring systems.

Adverse-event reporting and signal detection

The raw material of pharmacovigilance is adverse-event reporting: healthcare professionals, manufacturers and sometimes patients report suspected adverse reactions to spontaneous-reporting systems. Analysts then look for safety signals — patterns suggesting a previously unrecognised or changing risk associated with a medicine. Signal detection combines this reported data with other sources and statistical methods to distinguish genuine concerns from background noise. A confirmed signal can lead to further investigation, updated product information, restrictions, or in serious cases a recall.

Pharmacovigilance in the lifecycle

Pharmacovigilance is part of the wider regulatory and quality framework that governs a medicine across its lifecycle. Companies are required to maintain pharmacovigilance systems, submit periodic safety reports, and act on emerging risks, all under regulatory oversight. The discipline draws on pharmacology and epidemiological methods to interpret patterns of harm.

Its purpose is population-level risk management — protecting public health by ensuring that what is known about a medicine’s safety stays current. Like the rest of this pillar, it describes how the safety system works and is not guidance for individual treatment decisions.